In NPM-ALK-positive ALCL cell models, ALK inhibitor treatments (crizotinib, alectinib) were found to significantly increase the cell surface expression of HLA-A/B/C [53]. The gene discussed is HLA-A; the disease is anaplastic large cell lymphoma.